State of the Network

Sharon Nachman, MD
IMPAACT Network Chair
22 June 2021
William “Bill” Borkowsky
1947-2021
State of the Network: A Snapshot

- IMPAACT in the context of COVID-19
- Network activities and achievements in the past two years
- Study updates and achievements
- Continued and new partnerships
IMPAACT’s Goals

To improve health outcomes for infants, children, adolescents and pregnant/postpartum women who are impacted by or living with HIV by evaluating novel treatments and interventions for HIV and its complications and for tuberculosis and other HIV-related conditions.
IMPAAACT in the context of HIV and COVID-19
Accrual into all IMPAACT studies was paused in March 2020 and resumed in most studies beginning in July 2020, with careful consideration of study conduct in the context of the pandemic and detailed guidance issued for participating sites.

Ongoing studies continued with high rates of visit completion and protocol compliance and minimal disruption thanks to the awesome diligence and dedication of site staff!!

The safety and well-being of participants, study staff and their communities remains of utmost importance.
Response to COVID-19

In addition to implementing ongoing studies in the context of COVID-19, accrual has been initiated or resumed in five studies.
Study Highlight: IMPAACT 2032
Remdesivir in Pregnant and Non-Pregnant Women

- Rapidly developed with separate funding through the RADx-UP Initiative (Rapid Acceleration of Diagnostics for Underserved Populations)
- First participant enrolled on 31 March 2021 at JHU site (5092)
- 18 participants enrolled at 4 sites in the US through 31 May 2021

Anticipate complete accrual by September 2021
IMPAAACT Activities and Achievements in the Past Two Years
Successful Re-Competitions!

- The IMPAACT Network was awarded the grant for another seven years of support by the National Institutes of Health.
- Clinical Research Sites continuing, with the same overall number in the same locations (26 international sites; 19 in the US).

NIH Announces Restructured HIV Clinical Trials Networks

Grant Awards Set Stage for Next Seven Years of Science-Driven HIV Clinical Research

IMPAACT Annual Meeting 2021
Contributions to Expanded Treatment Options

- Three studies have had recent regulatory submissions (P1090/ETV, P1093/DTG, IMPAACT 2007/MVC)
- Two additional studies (IMPAACT 2014/DOR, 2017/CAB+RPV) are anticipated to be submitted within the next year
- Over the course of the last grant cycle and moving forward: 12 licensure studies, some with multiple regulatory submissions (RAL, DTG, ETV, MVC, DOR, CAB/RPV, DTG/ABC/3TC, DTG/RPV, remdesivir)
Current Portfolio
includes evaluation of the following interventions/agents

**Treatment**
- DTG/RPV in Children
- DTG in Neonates, Infants, Children and Adolescents
- Selected ARV and TB drugs in Pregnant/Postpartum Women
- ABC/DTG/3TC in Children
- LA CAB/RPV in Children
- DOR/3TC/TDF in Children
- Oral PrEP (TDF/FTC) in Pregnant & Postpartum Women
- bNAbs in Infants

**Tuberculosis**
- VPM1002/BCG in Pre-Adolescents
- Pretomanid in Children
- RPT/INH in Children
- BDQ in Children
- DLM in Children
- RPT/INH in Pregnant/Postpartum Women

**Complications**
- RSV vaccines in children
- Group-based counseling intervention in treatment non-adherent Adolescents

**Cure**
- LPV and NVP containing early intensive treatment, RAL and NVP containing early intensive treatment, and VRC01 in Infants
- Cord Blood Transplantation with CCR5Δ32 Donor Cells
# Current Portfolio

## 30 active studies

<table>
<thead>
<tr>
<th>Category</th>
<th>Protocols in Development</th>
<th>Pending and Open</th>
<th>Enrolling</th>
<th>Follow-Up</th>
<th>Closed to Follow-Up*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complications</td>
<td></td>
<td>2016</td>
<td>2021</td>
<td></td>
<td>2018</td>
</tr>
<tr>
<td>Cure</td>
<td></td>
<td>2028</td>
<td>P11115</td>
<td>P1107</td>
<td>2008</td>
</tr>
<tr>
<td>COVID-19</td>
<td></td>
<td></td>
<td>2032</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Approximately 30 additional studies and ancillary studies (NWCS, DACS, DR) in analysis and manuscript writing phase

*closed to follow-up in the last year
IMPAAACT Participants on Study
June 2019 to May 2020

Total On Study = 1,191 participants
Newly Enrolled = 247 participants
IMPAAACT Participants on Study
June 2020 to May 2021 (during pandemic)

Total On Study = 603 participants
Newly Enrolled = 197 participants
Study Updates and Achievements
Study Highlight: P1093
PK, Safety, & Antiviral Activity of Dolutegravir

- Landmark study of child-friendly dolutegravir formulations in children that continues to contribute to FDA and EMA approvals, with ODYSSEY study
- Completed accrual with 181 participants enrolled at 35 sites in Botswana, Brazil, Kenya, South Africa, Tanzania, Thailand, Uganda, the United States, and Zimbabwe
Study Highlight: P1108
PK and Safety of Bedaquiline in Infants, Children, and Adolescents with MDR-TB Disease and with or without HIV

- Addressing critical need for better medications to treat children with MDR-TB
- All five sites approved to resume accrual during the COVID-19 pandemic
- 15 participants enrolled in the past year with 30 evaluable enrolled overall

Anticipate Version 2 issued by July with accrual completion by September 2022

IMPAACT Annual Meeting 2021
Study Highlight: P1112

Safety and PK Parameters of Potent Anti-HIV Neutralizing Monoclonal Antibodies

- First of its kind monoclonal antibody study of potential early intervention among infants exposed to HIV
- 83 participants enrolled at sites in South Africa, the United States, and Zimbabwe
- Results from Dose Group 4 recently published in JID

Anticipate completing follow-up by February 2022
Study Highlight: P1115
Very Early Intensive Treatment of Infants with HIV to Achieve HIV Remission

- Network’s flagship proof-of-concept study for HIV remission in infants
- 76 mother-infant pairs have enrolled since accrual was approved to resume

- 18 sites have met requirements to resume accrual during pandemic
  - Accrual into Steps 1 and 2 approved to resume in July 2020
  - Entry into Step 3 approved on a site-by-site basis in May 2021

Anticipate enrollment completion by December 2023
Study Highlight: IMPAACT 2008

Study of Monoclonal Antibody Combined with ART

- First to evaluate monoclonal antibodies for treatment (and potential remission) in infants living with HIV
- 61 infants enrolled in Botswana, Brazil, Malawi, and Zimbabwe

Successfully completed follow-up as of 11 February 2021
Study Highlight: IMPAACT 2014

Doravirine as Fixed-Dose Combination for Adolescents

- New fixed-dose, one-pill/once-a-day combination for adolescents
- 10 participants enrolled at 4 sites in the US in Cohort 1
- 45 participants enrolled at 5 sites in South Africa, Thailand, and the US in Cohort 2

Anticipate completing follow-up by December 2021
Study Highlight: IMPAACT 2017
PK & Safety of Long-Acting Injectable Cabotegravir & Rilpivirine

▶ First study of long-acting injectable regimens in adolescents with HIV
▶ 24 adolescents and 10 parents/caregivers enrolled at 8 sites in the United States
▶ International sites working on approvals to start enrolling

Anticipate completing accrual by July 2022
Study Highlight: IMPAACT 2019

ABC/DTG/3TC as Fixed-Dose Combination for Children

- New fixed-dose, dispersible, once-a-day combination for young children
- Fully enrolled but pending confirmation of evaluability for lowest weight band
- Participants enrolled at 15 sites in Botswana, Thailand, South Africa, and United States

55 enrolled
Study Highlight: IMPAACT 2021
RSV Candidate Vaccine Study

- Randomized, Phase I/II placebo-controlled study among healthy RSV-seronegative children 6-24 months of age to assess safety and immunogenicity of candidate vaccines
- 30 of 160 participants enrolled at 10 sites in the US prior to accrual pause due to COVID-19
- Team, Network leadership, and sites in discussion on appropriate timeline to resume accrual in the United States (anticipated soon)

Anticipate issuance of Protocol Version 2 by Q3 2021
Community Engagement

- Community representation and input on all network groups and levels – clinical research sites, leadership groups, scientific and other committees, protocol teams, cross-network activities

- ICAB ensures that the principles of community participation and partnership are at the foundation of all community engagement activities and provides community input throughout the research process (concept development, study implementation, and results dissemination)
Successful IMPAACT Community Advisory Board Leadership Transition

- Emanueli Msuya transitioned from Vice Chair of the ICAB Leadership Group to Chair
- Jayshawnda Arrington voted by ICAB members as Vice Chair
- New leadership group representatives voted by ICAB members

IMPAACT Annual Meeting 2021
Publications

- 65 publications submitted for IMPAACT review in past 12 months
Abstracts

14 at CROI 2020, 7 at AIDS 2020, 8 at CROI 2021
- 3 abstracts from IMPAACT 2010/VESTED
- 2 abstracts from PROMISE and 2 abstracts from P1106

IMPAACT 2014 24-week PK and Safety of Doravirine/3TC/TDF in Adolescents with HIV-1

Lameck Chinula, Sean Brummel, Lauren Ziemia, Katie McCarthy, Benjamin Johnston, Nahida Chakhktours, Patrick Jean-Philippe, Lynda Strasu-Gribanda, Violet Konjano, Reessa Cassim, Lee Fairlie, Gaeulwe Masheto, Paul Sac, Judith S. Currier, Shahin Lockman

Safety/Efficacy of DTG vs EFV, TDF vs TAF in Pregnancy/Postpartum: IMPAACT 2010

Optimizing Dolutegravir Initiation in Neonates using Population Pharmacokinetic Modeling

Additional abstracts accepted to upcoming meetings at IAS 2021 and the HIV Pediatrics Workshop
Cross Network Study Initiatives

- Pregnancy Studies (IMPAACT 2026)
- MDR-TB Prevention (PHOENIX)
- TB Vaccine Studies (IMPAACT 2036)
- Dolutegravir (P1093/ODYSSEY)
- RSV and VRC Studies (IMPAACT 2011/2012/2013, IMPAACT 2018, IMPAACT 2021; P1112, IMPAACT 2008)
Pharma and Other Collaborations

IMPAACT Annual Meeting 2021
Plans for the Upcoming Year

- Finalize IMPAACT 2023 and 2029
- Finalize IMPAACT 2034 and 2035
- Finalize IMPAACT 2005 amendments
- Complete accrual in IMPAACT 2019 and 2032
- Complete activating IMPAACT 2017 sites
- Initiate IMPAACT 2026 and 2028
- Initiate PrEP Comparison Component of IMPAACT 2009
- Publish IMPAACT 2008, 2010, and 2018 results
- Continue supporting sites during COVID-19 pandemic
- Publish P1026s, P1080, PROMISE, and P1106 results
- Continue follow-up in P1112
- Continue follow-up in IMPAACT 2014 and P1107
- Continue enrollment in P1115
- Complete follow-up in IMPAACT 2014 and P1107
- Continue follow-up in P1093 and P1112
- Finalize and begin implementing IMPAACT 2023 and 2029
Thank you to site staff, to the communities, and to all of the individuals and families engaged in clinical research!

Let’s continue to move the science forward!
THANKS!
Any questions?